건강과 대안 » Pharmaceutical http://www.chsc.or.kr 연구공동체 Mon, 13 Apr 2026 01:34:28 +0000 ko-KR hourly 1 http://wordpress.org/?v=3.5.2 [제약기업] 위키리크스 : 화이자가 임상실험 배상을 회피하기 위,해 더러운 술책을 부리다. http://www.chsc.or.kr/?post_type=reference&p=2402 http://www.chsc.or.kr/?post_type=reference&p=2402#comments Fri, 10 Dec 2010 15:59:49 +0000 건강과대안 http://www.chsc.or.kr/?post_type=reference&p=2402

  • 위키리크스의 화이자관련 내용 <가디언> 보도. 

  • 전세계 1위 제약회사인 화이자(Pfizer)가 나이지리아에서 진행된 불법 임상실험에 대한 손해배상소송을 막기 위해 나이지리아 법무장관의 부패를 이용 협박하려 했다는 화이자측과 미국대사관의 2009년 4월 회의 내용 등.

  • 화이자는 1996년 유럽에서 성인용으로만 허가된 Trovan 이라는 항생제로 100명의 나이지리아 어린이들 대상의 뇌막염을 치료 임상실험을 시행. 부모의 동의도 받지않은 임상시험으로 확인된 숫자만 5명의 어린이들 사망. 

  • Trovan은 결국 간독성으로 시장에서 철수

  • 이런 더러운 술책으로 60억달러 규모의 소송이 결국 나이지리아와 화이자의 비밀합의로 7500만 달러 배상으로 2009년 종료되었다는 내용.

  • 당시 나이지리아 언론은 소송이 취하되고 배상으로 합의되자 “법무장관과 화이자의 비밀거래”라고 헤드라인으로 보도함.

  • 이 과정에서 화이자측은 국경없는 의사회가 그 실험에 참여했다고 비난했으나 국경없는 의사회측은 화이자가 그런 약을 사용하여 임상실험을 하는 것으로고 경악하여 이를 알렸다고 반박했다는 내용도 포함.

    • http://www.guardian.co.uk/business/2010/dec/09/wikileaks-cables-pfizer-nigeria

    WikiLeaks cables: Pfizer used dirty tricks to avoid clinical trial payout

    Cables say drug giant
    hired investigators to find evidence of corruption on Nigerian attorney
    general to persuade him to drop legal action

    • Sarah Boseley, health editor
    • guardian.co.uk,

    • Article history
      • Kano, in northern Nigeria, saw a meningitis epidemic of unprecedented scale in 1996

      Kano, in northern Nigeria, saw a meningitis
      epidemic of unprecedented scale in 1996. Photograph: Pius Utomi
      Ekpei/AFP/Getty Images

      The world’s biggest pharmaceutical company hired investigators to
      unearth evidence of corruption against the Nigerian attorney general in
      order to persuade him to drop legal action over a controversial drug
      trial involving children with meningitis, according to a leaked US embassy cable.

      Pfizer
      was sued by the Nigerian state and federal authorities, who claimed
      that children were harmed by a new antibiotic, Trovan, during the trial,
      which took place in the middle of a meningitis epidemic of
      unprecedented scale in Kano in the north of Nigeria in 1996.

      Last year, the company came to a tentative settlement with the Kano state government which was to cost it $75m.

      But
      the cable suggests that the US drug giant did not want to pay out to
      settle the two cases – one civil and one criminal – brought by the
      Nigerian federal government.

      The cable reports a meeting
      between Pfizer’s country manager, Enrico Liggeri, and US officials at
      the Abuja embassy on 9 April 2009. It states: “According to Liggeri,
      Pfizer had hired investigators to uncover corruption links to federal
      attorney general Michael Aondoakaa to expose him and put pressure on him
      to drop the federal cases. He said Pfizer’s investigators were passing
      this information to local media.”

      The cable, classified confidential by economic counsellor Robert Tansey, continues:
      “A series of damaging articles detailing Aondoakaa’s ‘alleged’
      corruption ties were published in February and March. Liggeri contended
      that Pfizer had much more damaging information on Aondoakaa and that
      Aondoakaa’s cronies were pressuring him to drop the suit for fear of
      further negative articles.”

      The release of the Pfizer cable came as:

      •
      The American ambassador to London denounced the leak of classified US
      embassy cables from around the world. In tomorrow’sGuardian Louis Susman
      writes: “This is not whistleblowing. There is nothing laudable about
      endangering innocent people. There is nothing brave about sabotaging the
      peaceful relations between nations on which our common security
      depends.”

      • It emerged that Julian Assange had been transferred to the segregation unit in Wandsworth prison and had distanced WikiLeaks from cyber attacks on MasterCard, Visa, PayPal and other organisations.

      •
      Other newly released cables revealed that China is losing patience with
      the failure of the Burmese regime to reform, and disclosed US fears
      that Europe will cave in to Serbian pressure to partition Kosovo.

      While
      many thousands fell ill during the Kano epidemic, Pfizer’s doctors
      treated 200 children, half with Trovan and half with the best meningitis
      drug used in the US at the time, ceftriaxone. Five children died on
      Trovan and six on ceftriaxone, which for the company was a good result.
      But later it was claimed Pfizer did not have proper consent from parents
      to use an experimental drug on their children and there were questions
      over the documentation of the trial. Trovan was licensed for adults in
      Europe, but later withdrawn because of fears of liver toxicity.

      The
      cable claims that Liggeri said Pfizer, which maintains the trial was
      well-conducted and any deaths were the direct result of the meningitis
      itself, was not happy about settling the Kano state cases, “but had come
      to the conclusion that the $75m figure was reasonable because the suits
      had been ongoing for many years costing Pfizer more than $15m a year in
      legal and investigative fees”.

      In an earlier meeting on 2 April
      between two Pfizer lawyers, Joe Petrosinelli and Atiba Adams, Liggeri,
      the US ambassador and the economic section, it had been suggested that
      Pfizer owed the favourable outcome of the federal cases to former
      Nigerian head of state Yakubu Gowon.

      He had interceded on Pfizer’s
      behalf with the Kano state governor, Mallam Ibrahim Shekarau – who
      directed that the state’s settlement demand should be reduced from $150m
      to $75m – and with the Nigerian president. “Adams reported that Gowon
      met with President Yar’Adua and convinced him to drop the two federal
      high court cases against Pfizer,” the cable says.

      But five days later Liggeri, without the lawyers present, enlarged on the covert operation against Aondoakaa.

      The cable says Liggeri went on to suggest that the lawsuits against Pfizer “were wholly political in nature”.

      He
      alleged that Médecins sans Frontières, which was in the same hospital
      in Kano, “administered Trovan to other children during the 1996
      meningitis epidemic and the Nigerian government has taken no action”.

      MSF
      – which was the first to raise concerns about the trial – vehemently
      denies this. Jean-Hervé Bradol, former president of MSF France, said:
      “We have never worked with this family of antibiotic. We don’t use it
      for meningitis. That is the reason why we were shocked to see this trial
      in the hospital.”

      There is no suggestion that the attorney
      general was swayed by the pressure. However, the dropping of the federal
      cases provoked suspicion in Nigeria. Last month, the Nigerian newspaper
      Next ran a story headlined, “Aondoakaa’s secret deal with Pfizer”.

      The
      terms of the agreement that led to the withdrawal of the $6bn federal
      suit in October 2009 against Pfizer “remain unknown because of the
      nature of [the] deal brokered by … Mike Aondoakaa”, it said. Pfizer and
      the Nigerian authorities had signed a confidentiality agreement. “The
      withdrawal of the case, as well as the terms of settlement, is a highly
      guarded secret by the parties involved in the negotiation,” the article
      said.

      Aondoakaa expressed astonishment at the claims in the US
      cable when approached by the Guardian. “I’m very surprised to see I
      became a subject, which is very shocking to me,” he said. “I was not
      aware of Pfizer looking into my past. For them to have done that is a
      very serious thing. I became a target of a multinational: you are
      supposed to have sympathy with me … If it is true, maybe I will take
      legal action.”

      In a statement to the Guardian, Pfizer said: “The
      Trovan cases brought by both the federal government of Nigeria and Kano
      state were resolved in 2009 by mutual agreement. Pfizer negotiated the
      settlement with the federal government of Nigeria in good faith and its
      conduct in reaching that agreement was proper. Although Pfizer has not
      seen any documents from the US embassy in Nigeria regarding the federal
      government cases, the statements purportedly contained in such documents
      are completely false.

      “As previously disclosed in Pfizer’s 10-Q
      filing in November 2009, per the agreement with the federal government,
      Nigeria dismissed its civil and criminal actions against the company.
      Pfizer denied any wrongdoing or liability in connection with the 1996
      study. The company agreed to pay the legal fees and expenses incurred by
      the federal government associated with the Trovan litigation. Pursuant
      to the settlement, payment was made to the federal government’s counsel
      of record in the case, and there was no payment made to the federal
      government of Nigeria itself. As is common practice, the agreement was
      covered by a standard confidentiality clause agreed to by both parties.”

       

    ]]>     http://www.chsc.or.kr/?post_type=reference&p=2402/feed 0